These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33674067)

  • 1. Future directions in drug development in pancreatic cancer.
    Lambert A; Conroy T; Ducreux M
    Semin Oncol; 2021 Feb; 48(1):47-56. PubMed ID: 33674067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
    Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
    Christenson ES; Jaffee E; Azad NS
    Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials.
    Kaur J; Singh P; Enzler T; Sahai V
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):103-129. PubMed ID: 33734833
    [No Abstract]   [Full Text] [Related]  

  • 6. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease.
    Tsai S; Christians KK; Ritch PS; George B; Khan AH; Erickson B; Evans DB
    J Oncol Pract; 2016 Oct; 12(10):915-923. PubMed ID: 27858562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic adenocarcinoma: Beyond first line, where are we?
    Cherri S; Noventa S; Zaniboni A
    World J Gastroenterol; 2021 May; 27(17):1847-1863. PubMed ID: 34007126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
    Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
    BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.
    Yu S; Zhang C; Xie KP
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188461. PubMed ID: 33157162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic targets in pancreatic cancer.
    Lai E; Puzzoni M; Ziranu P; Pretta A; Impera V; Mariani S; Liscia N; Soro P; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Pireddu A; Demurtas L; Pusceddu V; Camera S; Sclafani F; Scartozzi M
    Cancer Treat Rev; 2019 Dec; 81():101926. PubMed ID: 31739115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current progress in immunotherapy for pancreatic cancer.
    Foley K; Kim V; Jaffee E; Zheng L
    Cancer Lett; 2016 Oct; 381(1):244-51. PubMed ID: 26723878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current standards and new innovative approaches for treatment of pancreatic cancer.
    Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
    Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines.
    Okusaka T; Furuse J
    J Gastroenterol; 2020 Apr; 55(4):369-382. PubMed ID: 31997007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic developments in pancreatic cancer: current and future perspectives.
    Neoptolemos JP; Kleeff J; Michl P; Costello E; Greenhalf W; Palmer DH
    Nat Rev Gastroenterol Hepatol; 2018 Jun; 15(6):333-348. PubMed ID: 29717230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug development and clinical trial design in pancreatico-biliary malignancies.
    Harrington J; Carter L; Basu B; Cook N
    Curr Probl Cancer; 2018; 42(1):73-94. PubMed ID: 29402439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.
    Li X; Ma Q; Xu Q; Duan W; Lei J; Wu E
    Curr Pharm Des; 2012; 18(17):2404-15. PubMed ID: 22372501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
    Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.